Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -44.02% is 76% below its 5-year average of -24.96%, near the low end of its 5-year range (-44.02%–-9.15%).
As of the fiscal period ended Tuesday, June 30, 2026. 32.93% below its 12-month average of -33.11%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -44.02%.
RETURN ON EQUITY (ROE)
-44.02%
RETURN ON EQUITY (ROE) AVG TTM
-33.11%
RETURN ON EQUITY (ROE) AVG 3Y
-28.41%
RETURN ON EQUITY (ROE) AVG 5Y
-24.96%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-32.93%
CURRENT VS 3Y AVG
-54.95%
CURRENT VS 5Y AVG
-76.33%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.30%
median of 668 covered companies
CURRENT VS SECTOR MEDIAN
-9.21%
vs the sector median at left
Edgewise Therapeutics, Inc.
Market Cap
$4.30B
Return on Equity (ROE)
-44.02%
TTM Avg
-33.11%
3Y Avg
-28.41%
5Y Avg
-24.96%
Market Cap
$4.40B
Return on Equity (ROE)
N/A
TTM Avg
-107.43%
3Y Avg
-58.28%
5Y Avg
-52.10%
Market Cap
$4.41B
Return on Equity (ROE)
-44.68%
TTM Avg
-52.94%
3Y Avg
-55.51%
5Y Avg
-46.01%
Market Cap
$4.42B
Return on Equity (ROE)
-42.32%
TTM Avg
-13.82%
3Y Avg
-5.11%
5Y Avg
-5.11%
Market Cap
$4.15B
Return on Equity (ROE)
14.23%
TTM Avg
-7.71%
3Y Avg
-5.30%
5Y Avg
-10.52%
Market Cap
$4.07B
Return on Equity (ROE)
-18.38%
TTM Avg
-15.28%
3Y Avg
-7.60%
5Y Avg
-0.19%
Market Cap
$4.56B
Return on Equity (ROE)
6.24%
TTM Avg
-11.62%
3Y Avg
-98.18%
5Y Avg
-98.18%
Market Cap
$4.07B
Return on Equity (ROE)
-32.14%
TTM Avg
-46.09%
3Y Avg
-42.05%
5Y Avg
-35.94%
Market Cap
$4.66B
Return on Equity (ROE)
16.63%
TTM Avg
15.37%
3Y Avg
15.09%
5Y Avg
11.91%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Edgewise Therapeutics, Inc. (EWTX) | $4.30B | -44.02% | -33.11% | -28.41% | -24.96% |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.40B | N/A | -107.43% | -58.28% | -52.10% |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.41B | -44.68% | -52.94% | -55.51% | -46.01% |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.42B | -42.32% | -13.82% | -5.11% | -5.11% |
| LivaNova PLC (LIVN)vs › | $4.15B | 14.23% | -7.71% | -5.30% | -10.52% |
| AbCellera Biologics Inc. (ABCL)vs › | $4.07B | -18.38% | -15.28% | -7.60% | -0.19% |
| BillionToOne, Inc. (BLLN)vs › | $4.56B | 6.24% | -11.62% | -98.18% | -98.18% |
| Relay Therapeutics, Inc. (RLAY)vs › | $4.07B | -32.14% | -46.09% | -42.05% | -35.94% |
| Option Care Health, Inc. (OPCH)vs › | $4.66B | 16.63% | 15.37% | 15.09% | 11.91% |
| ICU Medical, Inc. (ICUI)vs › | $3.96B | 1.40% | -2.98% | -2.73% | 0.21% |
ROE
-44.0%
ROA
-41.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -44.02% |
| 2026-03-31 | -35.69% |
| 2025-12-31 | -32.13% |
| 2025-09-30 | -28.15% |
| 2025-06-30 | -25.58% |
| 2025-03-31 | -34.00% |
| 2024-12-31 | -29.14% |
| 2024-09-30 | -25.42% |
| 2024-06-30 | -22.70% |
| 2024-03-31 | -19.79% |
| 2023-12-31 | -31.42% |
| 2023-09-30 | -30.79% |
| 2023-06-30 | -26.08% |
| 2023-03-31 | -23.06% |
| 2022-12-31 | -19.51% |
| 2022-09-30 | -16.86% |
| 2022-06-30 | -22.88% |
| 2022-03-31 | -19.46% |
| 2021-12-31 | -15.60% |
| 2021-09-30 | -12.77% |
| 2021-06-30 | -9.15% |
| 2021-03-31 | -6.77% |
